Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T45993
|
||||
Former ID |
TTDS00163
|
||||
Target Name |
Calcium channel
|
||||
Target Type |
Successful
|
||||
Disease | Alzheimer disease [ICD9: 331; ICD10: G30] | ||||
Arrhythmia [ICD9: 427; ICD10: I47-I49] | |||||
Angina pectoris [ICD9: 413; ICD10: I20] | |||||
Allergy [ICD9: 995.3; ICD10: T78.4] | |||||
Bipolar disorder [ICD9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 300; ICD10: F31, F40-F42] | |||||
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | |||||
Cardiac arrhythmias [ICD9: 427; ICD10: I47-I49] | |||||
Chronic stable angina [ICD9: 413; ICD10: I20] | |||||
Cerebral vasospasm [ICD9: 443.9; ICD10: I73.9] | |||||
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3] | |||||
Cardiovascular disorder [ICD10: I00-I99] | |||||
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63] | |||||
Epilepsy [ICD10: G40] | |||||
Glaucoma [ICD9: 365; ICD10: H40-H42] | |||||
Hyperinsulinemia [ICD10: E16.1] | |||||
Hypertension [ICD9: 401; ICD10: I10-I16] | |||||
Heart failure [ICD9: 428; ICD10: I50] | |||||
Heart arrhythmia [ICD10: I47-I49] | |||||
High blood pressure; Angina [ICD9: 401, 413; ICD10: I10, I11, I12, I13, I15, I20] | |||||
Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10: A09, K58, K59.1] | |||||
Nerve injury [ICD10: T14.4] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Unspecified [ICD code not available] | |||||
BioChemical Class |
Voltage-gated ion channel
|
||||
Target Validation |
T45993
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Bepridil | Drug Info | Approved | Chronic stable angina | [536095], [539481] |
Clevidipine butyrate | Drug Info | Approved | Hypertension | [529941], [530865] | |
Felodipine | Drug Info | Approved | Hypertension | [467526], [538304] | |
Isradipine | Drug Info | Approved | Hypertension | [467728], [538323] | |
Nicardipine | Drug Info | Approved | High blood pressure; Angina | [538588], [539652] | |
Nimodipine | Drug Info | Approved | Cerebral vasospasm | [537115], [539643] | |
Nisoldipine | Drug Info | Approved | Hypertension | [538334], [539644] | |
DIPROTEVERINE HYDROCHLORIDE | Drug Info | Phase 3 | Angina pectoris | [530977] | |
Arverapamil | Drug Info | Phase 2 | Irritable bowel syndrome | [536224] | |
HBI-3000 | Drug Info | Phase 2 | Heart arrhythmia | [523241] | |
Nexopamil | Drug Info | Phase 2 | Hypertension | [533605] | |
S-2150 | Drug Info | Phase 2 | Angina pectoris | [525742] | |
CM2489 | Drug Info | Phase 1 | Psoriasis | [550394] | |
Elpetrigine | Drug Info | Phase 1 | Bipolar disorder | [548658] | |
YM-16151-4 | Drug Info | Phase 1 | Hypertension | [533693] | |
Rycals | Drug Info | Preclinical | Heart failure | [548909] | |
AE-0047 | Drug Info | Discontinued in Preregistration | Hypertension | [545033] | |
Monatepil maleate | Drug Info | Discontinued in Preregistration | Angina pectoris | [544922] | |
Palonidipine hydrochloride | Drug Info | Discontinued in Preregistration | Hypertension | [544802] | |
Semotiadil | Drug Info | Discontinued in Preregistration | Hypertension | [544577] | |
Anipamil | Drug Info | Discontinued in Phase 3 | Hypertension | [544597] | |
ELGODIPINE HYDROCHLORIDE | Drug Info | Discontinued in Phase 3 | Angina pectoris | [544620] | |
S-12968 | Drug Info | Discontinued in Phase 3 | Hypertension | [544583] | |
Tetrandrine | Drug Info | Discontinued in Phase 3 | Colorectal cancer | [548123] | |
AM336 | Drug Info | Discontinued in Phase 2 | Pain | [547107] | |
BRL-32872A | Drug Info | Discontinued in Phase 2 | Cardiac arrhythmias | [544642] | |
CD-349 | Drug Info | Discontinued in Phase 2 | Hypertension | [544582] | |
Dopropidil | Drug Info | Discontinued in Phase 2 | Angina pectoris | [544651] | |
FLOSATIDIL | Drug Info | Discontinued in Phase 2 | Angina pectoris | [546027] | |
Levosemotiadil | Drug Info | Discontinued in Phase 2 | Cardiac arrhythmias | [545959] | |
LIFARIZINE HYDROCHLORIDE | Drug Info | Discontinued in Phase 2 | Nerve injury | [545611] | |
S-312-d | Drug Info | Discontinued in Phase 2 | Epilepsy | [545128] | |
TAMOLARIZINE HYDROCHLORIDE | Drug Info | Discontinued in Phase 2 | Cognitive disorders | [544615] | |
CEREBROCRAST | Drug Info | Discontinued in Phase 1 | Nerve injury | [546142] | |
CERM-11956 | Drug Info | Discontinued in Phase 1 | Angina pectoris | [544570] | |
IGANIDIPINE HYDROCHLORIDE | Drug Info | Discontinued in Phase 1 | Glaucoma | [544613] | |
KT-362 | Drug Info | Discontinued in Phase 1 | Heart arrhythmia | [544621] | |
NP-252 | Drug Info | Discontinued in Phase 1 | Hypertension | [544612] | |
SM-6586 | Drug Info | Discontinued in Phase 1 | Hypertension | [545247] | |
SR-33805 | Drug Info | Discontinued in Phase 1 | Angina pectoris | [545199] | |
AHR-16303B | Drug Info | Terminated | Hypertension | [528509] | |
AHR-16462B | Drug Info | Terminated | Hypertension | [544614] | |
AJ-3941 | Drug Info | Terminated | Cerebrovascular ischaemia | [545131] | |
CD-832 | Drug Info | Terminated | Angina pectoris | [544928] | |
Clentiazem | Drug Info | Terminated | Angina pectoris | [544573] | |
Darodipine | Drug Info | Terminated | Cerebrovascular ischaemia | [544644] | |
DHP-218 | Drug Info | Terminated | Hypertension | [544647] | |
E-2050 | Drug Info | Terminated | Cerebrovascular ischaemia | [547437] | |
Emopamil | Drug Info | Terminated | Cerebrovascular ischaemia | [534257] | |
LAS-30538 | Drug Info | Terminated | Hyperinsulinemia | [526783] | |
NALTIAZEM HYDROCHLORIDE | Drug Info | Terminated | Angina pectoris | [544616] | |
NNC-09-0026 | Drug Info | Terminated | Cerebrovascular ischaemia | [545623] | |
NS-638 | Drug Info | Terminated | Cerebrovascular ischaemia | [545919] | |
NS-649 | Drug Info | Terminated | Alzheimer disease | [545918] | |
NS-696 | Drug Info | Terminated | Epilepsy | [545920] | |
Pranidipine | Drug Info | Terminated | Angina pectoris | [544610] | |
RS-93522 | Drug Info | Terminated | Hypertension | [545315] | |
RWJ-22108 | Drug Info | Terminated | Allergy | [545176] | |
RWJ-37868 | Drug Info | Terminated | Epilepsy | [546547] | |
SB-206284A | Drug Info | Terminated | Cerebrovascular ischaemia | [546310] | |
SB-237376 | Drug Info | Terminated | Arrhythmia | [526551] | |
SDZ-249482 | Drug Info | Terminated | Pain | [546809] | |
SIM-6080 | Drug Info | Terminated | Angina pectoris | [544566] | |
Siratiazem | Drug Info | Terminated | Angina pectoris | [545039] | |
SKF-96365 | Drug Info | Terminated | Angina pectoris | [539569], [544629] | |
SQ-33351 | Drug Info | Terminated | Hypertension | [545248] | |
UK-51656 | Drug Info | Terminated | Cardiovascular disorder | [545465] | |
VUF-8929 | Drug Info | Terminated | Heart failure | [546655] | |
Z-6568 | Drug Info | Terminated | Hypertension | [546236] | |
ZM-224832 | Drug Info | Terminated | Hypertension | [545336] | |
Modulator | AE-0047 | Drug Info | [534512] | ||
AGN-190744 | Drug Info | ||||
AHR-16303B | Drug Info | [528509] | |||
AHR-16462B | Drug Info | [551574] | |||
AJ-3941 | Drug Info | [534300] | |||
AM336 | Drug Info | ||||
Anipamil | Drug Info | [526808] | |||
Arverapamil | Drug Info | ||||
BELFOSDIL | Drug Info | ||||
Bepridil | Drug Info | [556264] | |||
BRL-32872A | Drug Info | ||||
CD-349 | Drug Info | [533370] | |||
CD-832 | Drug Info | [534624] | |||
CD-832.HCL | Drug Info | ||||
Clentiazem | Drug Info | ||||
Clevidipine butyrate | Drug Info | [529941], [530865] | |||
CM2489 | Drug Info | ||||
Darodipine | Drug Info | [533171] | |||
DHP-218 | Drug Info | [532637] | |||
Dopropidil | Drug Info | [531675] | |||
E-2050 | Drug Info | ||||
Emopamil | Drug Info | [534257] | |||
Isradipine | Drug Info | [556264] | |||
KT-362 | Drug Info | [528634] | |||
LAS-30538 | Drug Info | [526783] | |||
leualacin | Drug Info | ||||
Levosemotiadil | Drug Info | [525617] | |||
Monatepil maleate | Drug Info | [533755] | |||
NNC-09-0026 | Drug Info | [533857] | |||
NS-638 | Drug Info | [534103] | |||
NS-649 | Drug Info | [534454] | |||
NS-696 | Drug Info | [545921] | |||
Palonidipine hydrochloride | Drug Info | [533987] | |||
Pranidipine | Drug Info | [534602] | |||
RWJ-22108 | Drug Info | [534679] | |||
RWJ-37868 | Drug Info | [546548] | |||
Rycals | Drug Info | [544149] | |||
S-2150 | Drug Info | [525742] | |||
SB-206284A | Drug Info | [534379] | |||
SB-237376 | Drug Info | [526551] | |||
SDZ-249482 | Drug Info | [544057] | |||
Siratiazem | Drug Info | [533657] | |||
SKF-96365 | Drug Info | [531001] | |||
SQ-33351 | Drug Info | [545249] | |||
SR-33805 | Drug Info | [533840] | |||
SR-33805A | Drug Info | [534181], [551871] | |||
UK-51656 | Drug Info | [531460] | |||
VUF-8929 | Drug Info | [534538] | |||
YM-16151-4 | Drug Info | [533693] | |||
Z-6568 | Drug Info | [534223] | |||
ZM-224832 | Drug Info | [533916] | |||
Inhibitor | CEREBROCRAST | Drug Info | [530538], [551871] | ||
Antagonist | CERM-11956 | Drug Info | [533437], [551871] | ||
DIPROTEVERINE HYDROCHLORIDE | Drug Info | [534306], [551871] | |||
FLOSATIDIL | Drug Info | [551871] | |||
SM-6586 | Drug Info | [533969] | |||
Tetrandrine | Drug Info | [529052] | |||
Agonist | ELGODIPINE HYDROCHLORIDE | Drug Info | [527236], [551871] | ||
Blocker | Elpetrigine | Drug Info | [551057] | ||
Felodipine | Drug Info | [536912] | |||
HBI-3000 | Drug Info | [531239] | |||
IGANIDIPINE HYDROCHLORIDE | Drug Info | [525666], [551871] | |||
LIFARIZINE HYDROCHLORIDE | Drug Info | [534011], [551871] | |||
NALTIAZEM HYDROCHLORIDE | Drug Info | [529043], [551871] | |||
Nexopamil | Drug Info | [533605] | |||
Nicardipine | Drug Info | [537568] | |||
Nimodipine | Drug Info | [537329] | |||
Nisoldipine | Drug Info | [537487] | |||
NP-252 | Drug Info | [529006], [551871] | |||
RS-93522 | Drug Info | [530703], [551871] | |||
S-12968 | Drug Info | [530048] | |||
S-312-d | Drug Info | [526987] | |||
Semotiadil | Drug Info | [525787] | |||
SIM-6080 | Drug Info | [534236], [551871] | |||
TAMOLARIZINE HYDROCHLORIDE | Drug Info | [525821], [551871] | |||
TELUDIPINE HYDROCHLORIDE | Drug Info | [533748], [551871] | |||
References | |||||
Ref 467526 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4190). | ||||
Ref 467728 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4488). | ||||
Ref 523241 | ClinicalTrials.gov (NCT01235156) Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions. U.S. National Institutes of Health. | ||||
Ref 525742 | Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80. | ||||
Ref 526551 | Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21. | ||||
Ref 526783 | The calcium channel blocker LAS 30538, unlike nifedipine, verapamil, diltiazem or flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs. J Pharm Pharmacol. 1992 Oct;44(10):851-5. | ||||
Ref 528509 | AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53. | ||||
Ref 530865 | Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010 May;30(5):515-28. | ||||
Ref 530977 | Diproteverine (BRL 40015): a new type of calcium antagonist with potential antianginal properties. Eur J Pharmacol. 1991 Jan 17;192(3):317-27. | ||||
Ref 533605 | Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. | ||||
Ref 533693 | Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. | ||||
Ref 534257 | Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54. | ||||
Ref 536095 | New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. | ||||
Ref 536224 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | ||||
Ref 537115 | Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. | ||||
Ref 538304 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075896. | ||||
Ref 538323 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077169. | ||||
Ref 538334 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 079051. | ||||
Ref 538588 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022276. | ||||
Ref 539481 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2337). | ||||
Ref 539569 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2441). | ||||
Ref 539643 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2523). | ||||
Ref 539644 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2524). | ||||
Ref 539652 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2559). | ||||
Ref 544566 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000149) | ||||
Ref 544570 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000166) | ||||
Ref 544573 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000188) | ||||
Ref 544577 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000198) | ||||
Ref 544582 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000220) | ||||
Ref 544583 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000221) | ||||
Ref 544597 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000258) | ||||
Ref 544610 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000287) | ||||
Ref 544612 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000291) | ||||
Ref 544613 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000292) | ||||
Ref 544614 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000297) | ||||
Ref 544615 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000299) | ||||
Ref 544616 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000300) | ||||
Ref 544620 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000324) | ||||
Ref 544621 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000337) | ||||
Ref 544629 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000362) | ||||
Ref 544642 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000403) | ||||
Ref 544644 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000417) | ||||
Ref 544647 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000422) | ||||
Ref 544651 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000432) | ||||
Ref 544802 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001157) | ||||
Ref 544922 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001558) | ||||
Ref 544928 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001566) | ||||
Ref 545033 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001931) | ||||
Ref 545039 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001949) | ||||
Ref 545128 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002235) | ||||
Ref 545131 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002238) | ||||
Ref 545176 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002359) | ||||
Ref 545199 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002436) | ||||
Ref 545247 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002576) | ||||
Ref 545248 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577) | ||||
Ref 545315 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002793) | ||||
Ref 545336 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002886) | ||||
Ref 545465 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003366) | ||||
Ref 545611 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003892) | ||||
Ref 545623 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003940) | ||||
Ref 545918 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005353) | ||||
Ref 545919 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005354) | ||||
Ref 545920 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355) | ||||
Ref 545959 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005516) | ||||
Ref 546027 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005965) | ||||
Ref 546142 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006562) | ||||
Ref 546236 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007046) | ||||
Ref 546310 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007384) | ||||
Ref 546547 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896) | ||||
Ref 546655 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009533) | ||||
Ref 546809 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010408) | ||||
Ref 547107 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013107) | ||||
Ref 547437 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016308) | ||||
Ref 548123 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022136) | ||||
Ref 548658 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027454) | ||||
Ref 525617 | Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33. | ||||
Ref 525666 | Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits. CurrEye Res. 2000 Feb;20(2):101-8. | ||||
Ref 525742 | Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80. | ||||
Ref 525787 | Thyroid hypertrophic effect of semotiadil fumarate, a new calcium antagonist, in rats. J Toxicol Sci. 2000 May;25(2):121-30. | ||||
Ref 525821 | Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist. Jpn J Pharmacol. 2000 Mar;82(3):265-8. | ||||
Ref 526551 | Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21. | ||||
Ref 526783 | The calcium channel blocker LAS 30538, unlike nifedipine, verapamil, diltiazem or flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs. J Pharm Pharmacol. 1992 Oct;44(10):851-5. | ||||
Ref 526808 | Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):339-44. | ||||
Ref 526987 | Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol. 2004 Mar 15;67(6):1153-65. | ||||
Ref 527236 | The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1/Cip1) gene activation. FASEB J. 2004 Oct;18(13):1516-23. | ||||
Ref 528509 | AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53. | ||||
Ref 528634 | Comparative cardiac effects of KT-362 and verapamil in isolated heart--correlation to calcium channel current depression. J Cardiovasc Pharmacol. 1991 Oct;18(4):594-604. | ||||
Ref 529006 | Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Eur J Pharmacol.1991 Oct 22;203(3):337-44. | ||||
Ref 529043 | Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007 Sep;35(9):2071-5. | ||||
Ref 529052 | Tetrandrine: a novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells. Neuropharmacology. 1991 Dec;30(12A):1325-31. | ||||
Ref 530048 | (+)-S-12967 and (-)-S-12968: 1,4-dihydropyridine stereoisomers with calcium channel agonistic and antagonistic properties in rat resistance arteries. Br J Pharmacol. 1991 Jul;103(3):1703-8. | ||||
Ref 530538 | The dihydropyridine analogue cerebrocrast blocks both T-type and L-type calcium currents. Can J Physiol Pharmacol. 2009 Nov;87(11):923-32. | ||||
Ref 530703 | Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist. Pharm Res. 1991 Jan;8(1):134-5. | ||||
Ref 530865 | Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010 May;30(5):515-28. | ||||
Ref 531001 | The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br J Pharmacol. 2010 Jul;160(6):1464-75. | ||||
Ref 531239 | Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85. | ||||
Ref 531460 | Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. J Med Chem. 1990 Feb;33(2):585-91. | ||||
Ref 531675 | Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. Am J Cardiol. 1990 Sep 1;66(5):636-41. | ||||
Ref 532637 | Effect of DHP-218, a novel dihydropyridine phosphonate, on atrioventricular nodal conductivity compared with its vascular effect in dogs. J Cardiovasc Pharmacol. 1987 Sep;10(3):274-9. | ||||
Ref 533171 | Effect of cromakalim on contractions in rabbit isolated renal artery in the presence and absence of extracellular Ca2+. Br J Pharmacol. 1989 Dec;98(4):1303-11. | ||||
Ref 533370 | A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery. Jpn J Pharmacol. 1988 Dec;48(4):453-62. | ||||
Ref 533437 | The anti-ischaemic activity of the novel compound, CERM 11956, compared with that of bepridil and nifedipine in isolated guinea-pig hearts. Eur J Pharmacol. 1988 May 10;149(3):195-203. | ||||
Ref 533605 | Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. | ||||
Ref 533657 | Comparison of the effects of diltiazem and its analogue siratiazem on contractility in arteries, ileum and cardiac muscle. J Auton Pharmacol. 1995 Apr;15(2):107-13. | ||||
Ref 533693 | Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. | ||||
Ref 533748 | Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica. 1994 Jul-Aug;79(4):328-33. | ||||
Ref 533755 | Antihypertensive, antiatherosclerotic, and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1-adrenoceptor-blocking activity in experimental animals. Am J Hypertens. 1994 Oct;7(10 Pt 2):131S-40S. | ||||
Ref 533840 | Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52. | ||||
Ref 533857 | Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol Biochem Behav. 1994 May;48(1):77-85. | ||||
Ref 533916 | Diuretic and antihypertensive activity of ZENECA ZM224,832: a novel eukalemic diuretic with calcium channel blocking activity. Pharmacology. 1994 Mar;48(3):167-75. | ||||
Ref 533969 | Calcium channel blocking properties of SM-6586 in rat heart and brain as assessed by radioligand binding assay. Jpn J Pharmacol. 1993 Oct;63(2):165-9. | ||||
Ref 533987 | Effect of palonidipine hydrochloride (TC-81), a novel calcium antagonist, on the canine coronary artery. Nihon Yakurigaku Zasshi. 1993 Jul;102(1):23-33. | ||||
Ref 534011 | The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol. 1993 May;109(1):175-7. | ||||
Ref 534103 | Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res. 1995 Oct;17(5):353-60. | ||||
Ref 534181 | Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker. Cardiovasc Res. 1995 Dec;30(6):1038-43. | ||||
Ref 534223 | Determination of the dihydropyridine aryloxypropanolamine Z6568 and its acidic metabolites in plasma, urine and tissues by solid phase extraction and liquid chromatography/negative-ion mass spectrometry. J Mass Spectrom. 1996 Sep;31(9):994-1002. | ||||
Ref 534236 | Determination of the calcium antagonist SIM6080 and its N- and O-demethylated metabolites in plasma, urine and tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Feb 9;676(1):77-85. | ||||
Ref 534257 | Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54. | ||||
Ref 534300 | Prevention by the new Ca2+ channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid hemorrhage in rats. Eur J Pharmacol. 1996 Nov 21;315(3):297-303. | ||||
Ref 534306 | Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9. | ||||
Ref 534379 | The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J Cereb Blood Flow Metab. 1997 Apr;17(4):421-9. | ||||
Ref 534454 | Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31. | ||||
Ref 534512 | AE0047-mediated calcium channel blocking in vascular smooth muscles. Gen Pharmacol. 1997 Sep;29(3):337-43. | ||||
Ref 534538 | In vitro and in vivo characterization of a calcium modulator of the diphenylalkylamine type with selective coronary dilatory properties. Arzneimittelforschung. 1997 Nov;47(11):1211-8. | ||||
Ref 534602 | Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Mol Cell Biochem. 1998 Jan;178(1-2):335-43. | ||||
Ref 534624 | Effects of CD-832, a new calcium antagonist, on intracranial pressure in anesthetized dogs. Life Sci. 1998;62(19):PL283-8. | ||||
Ref 534679 | Design and discovery of RWJ 22108--a novel bronchoselective calcium channel blocker. Drug Des Discov. 1998 May;15(3):135-48. | ||||
Ref 536912 | Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. Epub 2008 Oct 30. | ||||
Ref 537329 | Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44. | ||||
Ref 537487 | RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12. | ||||
Ref 537568 | Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20. | ||||
Ref 544057 | Physiology and Pharmacology of the Vanilloid Receptor. Curr Neuropharmacol. 2006 January; 4(1): 1-15. | ||||
Ref 544149 | Fixing ryanodine receptor Ca2+ leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mech. 2010 SUMMER; 7(2): e151-e157. | ||||
Ref 545249 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577) | ||||
Ref 545921 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355) | ||||
Ref 546548 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896) | ||||
Ref 551574 | A pharmacological and biochemical examination of AHR-16462B, a novel calcium antagonist coronary vasodilator/antihypertensive. Drug Development Research. 01/1991; 22(3):259-271. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.